 |
|
|
|
LEO Pharma Inc. is a wholly-owned subsidiary of the LEO Foundation of Denmark. The Foundation is an independent Research Foundation specializing in dermatology, hemostasis, inflammation and oncology. The dermatology portfolio includes, Topical Fucidin*, which is today the highest prescribed topical antibiotic in Canada, Dovobet*/ Dovonex*, a leading treatment for psoriasis over the past 12 years, as well as Fucidin*H for mild to moderate Atopic Dermatitis. The Foundation prides itself in its’ ability to generate the highest quality of research to support its product claims. This has been accomplished through an active network of world-class researchers, including more than 200 dermatologists within the Canadian healthcare system. In this vein, LEO is committed to provide clinicians with the evidence to support the appropriate use of our medicines. *registered trademark of LEO Pharmaceutical Products used under license by LEO Pharma Inc., Thornhill, Ontario
Click here to close this window |